Among women with only minor risk factors, two thirds (35/50, 70.0%) had a combination of several risk factors; the median ...

Favorable safety shown in secondary prevention for acute venous thromboembolism ...

Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during three-month trial period.

Higher activity levels in the immediate postoperative recovery period after total knee arthroplasty may reduce the risk for ...

Acute venous embolism and thrombosis are both conditions that disrupt blood flow. Treatment may involve medications or surgery. Blood clot formation is a protective mechanism that helps prevent excess ...

Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...

In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.

A population-based study conducted in Spain has revealed that both adenovirus vector-based and messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines are associated with ...